Loading
A phase 1/2 trial of Cyclophosphamide, Doxorubicin, Vincristine in hodgkin lymphoma and non-hodgkin lymphoma, run by Evopoint Biosciences Inc., now recruiting.
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma is a phase 1/2 interventional study registered as NCT07730515 by Evopoint Biosciences Inc., with 176 participants planned, started 2025-08-15 and due to reach its primary completion in 2028-09-30. Interventions recorded: XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended), XNW5004 combined with CHOEP (extended). Conditions listed: Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prednisone, Vincristine, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Doxorubicin.
Shares XNW5004, Evopoint Biosciences, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Prednisone, Vincristine, Etoposide, Doxorubicin.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide.
Shares XNW5004, Evopoint Biosciences.
Shares Prednisone, Vincristine, Doxorubicin, Cyclophosphamide.
Shares Prednisone, Vincristine, Etoposide, Doxorubicin.
Shares Prednisone, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Doxorubicin, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/